Oncoheroes Biosciences Selected as Finalist for J.P. Morgan Life Sciences Innovation Summit

Oncoheroes Biosciences is proud to announce we have been selected as one of the eleven finalists of the inaugural J.P. Morgan Asset Management: Life Sciences Innovation Summit. Scheduled for May 14th–15th, 2024, at the Cleveland Clinic Abu Dhabi, this event aims to cultivate a thriving ecosystem for early-stage entrepreneurs in the life sciences sector.

The summit, sponsored by J.P. Morgan Life Sciences Private Capital, Blue Horizon Advisors, and United AlSaqer Group, coincides with the Abu Dhabi Global Healthcare Week, drawing top-tier innovators and investors from around the globe. With a focus on fostering scientific innovation in Abu Dhabi, the summit seeks to propel the growth of the region's life sciences industry.

Cesare Spadoni, Oncoheroes Biosciences’ co-founder and COO, will present Oncoheroes’ pioneering work to a panel of judges comprising industry leaders and investors, including Dr. Laurie Glimcher, President and CEO of the Dana-Farber Cancer Institute, Dr. Jorge Guzman, CEO of the Cleveland Clinic Abu Dhabi, Prof. Shahrukh Khurshid Hashmi, Director of Research at the Department of Health of Abu Dhabi, Dr. David Hung, President and CEO at Nuvation Bio, Dr. Yasmine Hayek Kobeissi, Executive Director at Blue Horizon Advisors, and Ms. Anya Schiess, Managing Partner at J.P. Morgan Life Sciences Private Capital. This recognition highlights Oncoheroes Biosciences' commitment to advancing novel treatments for childhood cancers.

Super Sam Foundation Reaffirms Support for Oncoheroes' Pediatric Cancer Drive

In June 2020, the Super Sam Foundation invested in Oncoheroes Biosciences, with the aim of advancing the development of new treatments for childhood cancer. Founded in honor of Sam, a courageous rhabdomyosarcoma fighter who ardently wished for better treatment options for "all the kids," the foundation has remained steadfast in its commitment to improving outcomes for children battling cancer.

As Oncoheroes prepares to evaluate the efficacy of its lead compound, volasertib, across five pediatric cancer indications, including rhabdomyosarcoma, the Super Sam Foundation once again steps forward to support our mission. With the latest grant provided by the foundation, the international clinical trial to assess volasertib is now one significant step closer to beginning.

Cassie Santhuff, president and co-founder of the Super Sam Foundation, expresses her support to Oncoheroes, stating, “At Super Sam Foundation, we are committed to funding meaningful research that moves the needle one step closer to saving more lives. Oncoheroes’ innovative approach to their work is both meaningful and effective in the fight to help all the kids who battle cancer. We are, once again, thrilled to partner with the team to continue our support for volasertib. This drug is full-circle for our Foundation, as we wish our Founding Hero, Sam, would have had this drug as an option during his fight 10 years ago. We are deeply appreciative of the incredible work Oncoheroes is doing in the childhood cancer community and excited to support their vital work”.

Together, with the support of partners like the Super Sam Foundation, Oncoheroes can continue to make meaningful strides in advancing pediatric cancer research. We want to express our genuine thanks to the Super Sam Foundation for their generous support and dedication to Oncoheroes' mission.

Thank You!

Oncoheroes Announces Advancement in Pediatric Cancer Research

Oncoheroes Biosciences is proud to announce a significant milestone in its mission to combat pediatric brain cancer. In a recent paper published in SLAS Discovery journal titled "Development of a High-Throughput Screening Platform to Identify New Therapeutic Agents for Medulloblastoma Group 3" authored by Inés Fallon, Henar Hernando, Olga Almacellas-Rabaiget, Berta Marti-Fuster, Cesare Spadoni, Darell D Bigner, and Eva Méndez, our team reveals the development of an innovative screening platform aimed at identifying potential drug candidates for medulloblastoma, a type of brain cancer prevalent in children

Medulloblastoma presents a formidable challenge in oncology due to its resistance to traditional treatments. Oncoheroes recognizes that early selection of compounds that effectively target cancer cells while sparing normal tissues is crucial for success in clinical trials. Addressing this challenge head-on, we have engineered a screening platform designed to minimize toxicity risks and advance molecules with the highest likelihood of efficacy and safety for patients. Cesare Spadoni, Oncoheroes’ Chief Operating Officer and co-founder elaborates, "The development of this platform signifies a pivotal step forward in our quest to accelerate pediatric oncology drug development. By prioritizing safety and efficacy, we aim to accelerate the translation of scientific discoveries into life-saving therapies".

The publication of our research in SLAS Discovery marks a significant achievement for Oncoheroes. Inés Fallon, the first author of the paper, expresses our team's enthusiasm, stating, "We are thrilled to contribute to the body of knowledge surrounding pediatric brain tumors. This publication underscores our commitment to collaboration and innovation in the fight against childhood cancer".

Caroline Symmes Children’s Cancer Endowment backs up Oncoheroes’ mission

Caroline Symmes was diagnosed with Wilms Tumor Disease a month before her fourth birthday. Throughout her treatments, her parents confronted the stark reality of childhood cancer, which posed unique challenges distinct from those of adult cancer. Despite the high cure rate associated with Caroline’s type of cancer, her aggressive tumor ultimately claimed her life.

Out of her tragedy, the Caroline Symmes Children's Cancer Endowment was established in 2014 to fund research and inspire hope in future pediatric patients and their families. Today the Teen Board explores unique efforts around the world focusing on cutting-edge organizations gaining prominence within the field of pediatric cancer research.

“Our Teen Board is honored and excited to be a part of Oncoheroes Biosciences journey of becoming the global leader in delivering new pediatric oncology drugs, along with expanding the Endowment’s reach beyond the Indianapolis, Indiana area”, stated Holyn Drook, Teen Board Chair, Philanthropy/Research Committee.

Oncoheroes extends its sincere gratitude to the Caroline Symmes Children’s Cancer Endowment and their Teen Board for their commitment to our shared mission. Thanks to this new grant, the international clinical trial to assess the efficacy of our lead-compound, volasertib, in five different types of pediatric cancer, is one step closer to launching.

The collaboration between the Caroline Symmes Children’s Cancer Endowment and Oncoheroes underscores a united front in the battle against pediatric cancer. Together, we strive to transform the landscape of childhood cancer treatment, offering new avenues of hope and healing for patients and their families.

Thank you!

Brittney’s Believers Foundation Joins Forces with Oncoheroes to Fight Childhood Cancer

Brittney Gail Bliss brought joy to all who knew her with her love for dress-up, crafting, and dance parties. Tragically, her life was cut short when she was diagnosed with Embryonal Rhabdomyosarcoma in May 2022. In her memory, her parents, Elena and Brian, established Brittney’s Believers Foundation, dedicated to raising funds and awareness for childhood cancer research.

 Now, Brittney’s Believers Foundation has joined forces with Oncoheroes to support the advancement of pediatric oncology. Their generous grant will contribute to the launch of an international clinical trial testing the efficacy of Oncoheroes' lead-compound, volasertib, in five different types of pediatric cancer, including rhabdomyosarcoma.

“We decided to partner with Oncoheroes because they are at the forefront in fighting childhood cancer! The work they are doing aligns with our mission in hopes of finding new and better ways to treat and one day defeat childhood cancer!”, stated Elena, Brittney’s mother.

Oncoheroes extends our deepest gratitude to Brittney’s Believers Foundation for their unwavering support. Together, we are committed to developing new therapies specifically tailored to pediatric oncology, offering hope to children battling cancer worldwide.

Thank you!

Rallying for a Cure: Oncoheroes Biosciences receives a grant from Rally Foundation

In 2005, Dean Crowe faced a question that would change lives: "What can I do to help?" This simple inquiry, posed to a friend whose 17-year-old son, William, was battling brain cancer for the second time, sparked the inception of Rally Foundation for Childhood Cancer Research. Moved by the urgency to make a difference, Dean embarked on a mission to raise funds for childhood cancer research. With a steadfast dedication to advancing pediatric cancer research, Rally Foundation has awarded an impressive $29.4 million in grants to institutions across the nation and around the globe. Each grant represents not just a monetary contribution, but a beacon of hope for children and families facing the unimaginable challenges of cancer.

In alignment with International Childhood Cancer Day, Dean Crowe, CEO and founder of Rally Foundation, announced that Oncoheroes Biosciences, has been selected as the recipient of a new grant. “Each grant funded by Rally Foundation for Childhood Cancer Research is chosen through a rigorous dual peer-review process. Rally’s Medical Advisory Board recognizes the promise of this international clinical trial and Oncoheroes’ lead compound that targets five different pediatric cancers. We are encouraged that this trial will bring hope to children and adolescents fighting cancer”, stated Dean.

This grant marks the third time Rally has provided crucial support to advance Oncoheroes’ mission of finding new and better therapies for childhood cancer. Since 2021, Rally Foundation has been a vital partner in Oncoheroes’ journey, investing in the company twice during that year alone. The grant will contribute to launch an international clinical trial to test the efficacy of Oncoheroes’ lead compound, volasertib, in five types of pediatric cancer. On behalf of Oncoheroes Biosciences, we extend our deepest gratitude to Rally Foundation for their support and unwavering belief in our mission.

Thank you!

Oncoheroes Biosciences: the pivotal role of non-profits in pediatric drug development

Oncoheroes Biosciences was founded by two fathers whose personal experiences with childhood cancer ignited a passionate vision for change. Recognizing the urgent need for dedicated advancement in pediatric oncology therapies, they embarked on a mission to make a difference.

Since its inception in 2017, Oncoheroes Biosciences has rapidly evolved, buoyed by the unwavering support of numerous foundations worldwide. With their backing, we've built a portfolio featuring three clinic-ready compounds, poised to address eight different types of pediatric cancer indications. Now, our primary goal is securing the necessary funding to propel the testing of our lead compound, volasertib, in five types of pediatric cancer (Ewing’s sarcoma, alveolar rhabdomyosarcoma, medulloblastoma, neuroblastoma and DMG including DIPG).

In collaboration with Hopp Children’s Cancer Center Heidelberg (KiTZ), this trial will span 20 sites across multiple countries, enrolling approximately 110 patients who have exhausted their treatment options.

We extend our deepest gratitude to all the non-profits, organizations, and individuals committed to our mission. Your steadfast support has been instrumental in our journey thus far, and we look forward to continuing this vital work together in the chapters ahead.

Thank You!

Rekindling Hope: Scott Carter Foundation and Oncoheroes Reunite to Tackle Pediatric Cancer

In September 2021, the Scott Carter Foundation decided to join Oncoheroes’ quest for new pediatric oncology treatments by investing in the company. After almost three years, coinciding with International Childhood Cancer Day, the foundation announced that it maintained its commitment to Oncoheroes. The Scott Carter Foundation will now provide a grant to support the launch of an international clinical trial to test the efficacy of Oncoheroes’ lead compound, Volasertib, in five different types of pediatric cancer. This clinical trial led by Hopp Children’s Cancer Center Heidelberg (KiTZ) represents a new beacon of hope for children and adolescents who have exhausted their treatment options.

Paula Carter, mom to Scott Carter, the brave 13 year-old who tragically passed away in 1993, after a three-year long battle against osteosarcoma, announced the foundation’s new support to Oncoheroes at the Oncothon event. “The Scott Carter Foundation has been dedicated to supporting  pediatric cancer research for thirty years.  It has been disheartening to find that some treatment protocols have not changed at all and to note that in the last three decades, only seven drugs have been approved specifically for pediatric cancer. It is incredible to partner with a company solely devoted to developing new treatments for these young patients. We're excited to announce our contribution of additional funds to expedite the launch of the Volasertib trial as soon as possible”, stated Paula.

We are profoundly thankful to the Scott Carter Foundation for their steadfast commitment and unwavering support in our joint endeavor to combat pediatric cancer. Their dedication shines as a guiding light, fueling our determination to explore new frontiers in research and innovation.

Thank You!

Empowering hope: Oncoheroes Biosciences and Foundation for Addie’s Research Renew Commitment to Transform Pediatric Cancer Treatments

The Foundation for Addie’s Research initiatied its partnership with Oncoheroes Biosciences in June 2022 providing crucial support for Oncoheroes’ initial strides towards advancing clinical development for its lead compound, Volasertib.

Today, the Foundation for Addie’s Research renews its commitment to Oncoheroes’ mission of discovering effective therapies for pediatric cancer patients by providing additional support to initiate a clinical trial to evaluate Volasertib’s effectiveness in treating five aggressive pediatric cancers. This international trial, organized in partnership with Hopp Children’s Cancer Center Heidelberg (KiTZ), will take place in different sites across Europe, the United Kingdom and Australia, and represents a new beacon of hope for children and adolescents who have exhausted their treatment options.

Christina Stiverson, President of the Foundation for Addie’s Research, conveyed her enthusiasm about this pivotal development, stating, 'We are extremely excited to see the Volasertib trial move forward from bench science to the bedside. After years of supporting pre-clinical research on Volasertib, we are grateful for our partnership with Oncoheroes to make this treatment available for patients with rare pediatric cancers.'

The Foundation for Addie’s Research stems from the brave journey of Adelaide, “Addie”, a courageous childhood cancer who battled Hepatoblastoma and saddly passed away in 2016 at the age of three. This foundation is focused on pre-clinical research and innovative trials aiming to expand treatment options for children facing circumstances similar to Addie’s. In addition, Foundation for Addie’s Research created the Hepatoblastoma Resource Network, a comprehensive resource hub designated to unite and support families within the fragmented rare cancer community.

Thank You!

Oncoheroes & Ally Anderson Alveolar Rhabdomyosarcoma Research Fund Supported by Arms Wide Open Childhood Cancer Foundation Join Forces to Test Volasertib’s Potential

250 children die from cancer every day across the globe. Childhood cancer is still the first cause of death by disease among children in the U.S. Despite this, there are only seven drugs specifically designed and approved for pediatric cancer. Oncoheroes Biosciences is now at a crucial moment in its quest to find effective therapies for pediatric cancer patients, as they have the unprecedented opportunity to test Volasertib, one of its three clinic-ready compounds, in a crucial clinical trial. This trial is not just any trial - it's a beacon of hope for children and adolescents who have exhausted all other treatment options, battling against five aggressive pediatric cancers: Ewing sarcoma, medulloblastoma, neuroblastoma, rhabdomyosarcoma, and diffuse midline glioma (DMG), including diffuse intrinsic pontine glioma (DIPG).

The Ally Anderson Alveolar Rhabdomyosarcoma (aRMS) Research Fund | AllyARMSFund.org established in honor of childhood cancer fighter, Ally Anderson, will dedicate its initial funds to support Oncoheroes. Ally’s battle against aRMS began five years ago, and her journey illuminated the pressing need for advancements in pediatric cancer research, specifically in aRMS, a focal point of Oncoheroes’ clinic-ready compound, Volasertib.

"A few days before Ally left us, Ally was determined to make a difference so other children could access what eluded her. Her foremost goal was to support Oncoheroes in launching Volasertib’s trial" stated Patty Anderson, Ally's mother. 

AllyARMSFund is supported by Arms Wide Open Childhood Cancer Foundation and its goal is to raise research funds to help find safer and less-toxic treatments for Alveolar Rhabdomyosarcoma. At Ally’s request, the initial funding will support Oncoheroes in its partnership with Hopp Children’s Cancer Center Heidelberg (KiTZ) to test Volasertib’s efficacy in several types of pediatric cancers, including Rhabdomyosarcoma. This basket trial, largely supported by Ein Herz für Kinder, would be the first comprehensive pediatric evaluation of this promising compound and would serve as the basis for a later global registration trial in the most suitable pediatric indication.

Thank You!

Foundation for Addie’s Research Joins Oncoheroes To Create More and Better Options for Children Fighting Cancer

Every year near 100,000 kids worldwide die of cancer, largely because of the lack of innovative treatments for the types of cancer affecting children and adolescents. Oncoheroes Biosciences, has built a multi-asset portfolio of drugs to potentially treat several types of childhood cancer that have had little significant improvement over the past 20-30 years in overall survival.

“We are passionate about cancer research combined with a sense of urgency. We have been researching Oncoheroes’ lead compound, volasertib, for several years and feel confident in its efficacy”, said Christina Stiverson, President of the Foundation for Addie’s Research. “The foundation is extremely excited to support Oncoheroes moving volasertib into a clinical trial  to create more and better options for children fighting cancer. This effort could have made a difference for my daughter Addie who ran out of available treatments”.

Adelaide “Addie” was a childhood cancer warrior who lost her battle with Hepatoblastoma in 2016 at the age of three. Foundation for Addie’s Research is focused on pre-clinical research and innovative trials to create more options for children like Addie.

In addition, Foundation for Addie’s Research created the Hepatoblastoma Resource Network, a credible consolidated resource for families, to unite a fractured rare cancer community.  “Last year we spearheaded the first ever virtual global conference bringing together researchers, clinicians, and parents from 18 different countries!” added  Christina Stiverson, President of the Foundation for Addie’s Research.

“We are encouraged by preclinical data showing volasertib could be used for other cancer indications beyond rhabdomyosarcoma, our initial planned trial. We are working with academic centers worldwide to explore other indications like DIPG, Ewing sarcoma, medulloblastoma, neuroblastoma and hepatoblastoma”, stated Cesare Spadoni, Co-Founder and COO of Oncoheroes Biosciences. ”We welcome Foundation for Addie’s Research to Oncoheroes and are excited to get aligned for the benefit of hepatoblastoma patients. Thank you, Foundation for Addie’s Research.”

Thank You!

Infinite Love For Kids Fighting Cancer Joins Oncoheroes Biosciences To Bring Hope to Pediatric Cancer Patients

Childhood Cancer is rare and not a single disease, with more than 12 major types of pediatric cancers and over 100 subtypes. Although pediatric cancer death rates have declined due to improved tumor detection and treatment, cancer is still one of the leading causes of death by disease among children and adolescents. Additionally, 95.5% of adults treated for cancer during childhood will likely have at least one chronic health condition by the age of 45 if better treatments are not developed. 

"Cure is often mentioned when people are discussing childhood cancer, and while this is the ultimate dream, what we really need right now is something much more tangible, a less toxic, more effective way of treating our children. That's why Infinite Love is proud to be partnering with Oncoheroes, the first company of its kind to focus 100% of its efforts on the development of new, innovative drugs specifically aimed towards our children,” said Andrea Verdone Gorsegner, President and Founder of Infinite Love for Kids Fighting Cancer. “I truly believe that Oncoheroes is going to be a game-changer for our little fighters, and I'm honored that Infinite Love will be a small part of their extraordinary work."

Infinite Love for Kids Fighting Cancer is a 100% volunteer run 501(c)(3) foundation that focuses on providing financial grants to US leading research hospitals and facilities (e.g., CBTM at the Children’s Hospital of Philadelphia, Memorial Sloan Kettering, Dana-Farber Cancer Institute, Yale University). Infinite Love focuses their fundraising efforts on a different form of childhood cancer every year since no two pediatric cancers are the same.  

"The organizations that we invest money in must foster the message of Infinite Love - that hope is precious and something that we all need. This partnership gives me hope and I am excited that it has the potential to spread this gift to future generations." added Jim McCaffrey, Vice President of Infinite Love for Kids Fighting Cancer.  

In addition to research, Infinite Love has also been able to help the very families affected by childhood cancer. Infinite Love strives to #MakeItAmazing every day in the best way they can, comforting childhood cancer families and making sure that they know that no one fights alone.

“Welcoming a non-profit aligned with our goal to defeat childhood cancer is exciting and reassuring every single time. We applaud the leadership of Infinite Love for supporting new paths to bring faster the highly needed therapies for children fighting cancer,” stated Ricardo Garcia, CEO of Oncoheroes Biosciences. ”Simply put, thank you, Infinite Love for Kids Fighting Cancer.”

Thank You!

Oncoheroes Biosciences Receives A Second Investment From Rally Foundation

In April 2021, Rally Foundation For Childhood Cancer Research invested for the first time in Oncoheroes Biosciences. Today, we are thrilled to announce that Rally Foundation is investing again based on the progress made by Oncoheroes’ team this year.   

Rally Foundation is a pediatric cancer non-profit focused on raising awareness and funds for childhood cancer research to find better treatments with fewer long-term side effects and, ultimately, cures. They fund the most promising and cutting-edge research initiatives around the globe, seeing themselves as philanthropic seed investors in the next great discoveries.

“In just eight months, we have witnessed Oncoheroes’ team achieve important milestones that reassured their industry expertise and commitment to pediatric cancer,” stated Dean Crowe, co-Founder, and CEO of Rally Foundation. “We cannot wait to see what Oncoheroes will accomplish in 2022 and how together we are accelerating childhood cancer drug development.”

In the last 16 years, Rally Foundation has awarded more than $22 million in childhood cancer research grants at hospitals and institutions worldwide and secured $31 million in new federal funding for cancers in children, adolescents, and young adults from the Department of Defense’s Medical Research Program.

“Now that we are approaching the end of the year, we are very happy that we have accomplished all that we planned for 2021. Receiving a new investment again from Rally Foundation is an acknowledgment of a good job and encourages us to be even more ambitious with our future milestones,” stated Ricardo Garcia, CEO of Oncoheroes Biosciences. ”Thanks, Rally Foundation, for reinforcing your support and Rally on.”

Thank You & Rally On!

Oncoheroes Biosciences receives a second investment from The Andrew McDonough B+ Foundation

In October 2019, The Andrew McDonough B+ Foundation invested for the first time in Oncoheroes Biosciences, a biotech company advancing new therapies for childhood cancer. The B+ Foundation was the first childhood cancer non-profit to join Oncoheroes. Today, we are excited to announce that The B+ Foundation is investing again after assessing the company's progress during this period.

“Two years ago, we invested in a project led by two dads touched by childhood cancer with an undoubted passion and commitment. We knew they would put their soul and hearts into this ambitious project leading a group of life sciences industry experts,” stated Joe McDonough, co-founder and Executive Director of The Andrew McDonough B+ Foundation. “Today, we are glad to reinforce our support towards Oncoheroes after their demonstrated team's execution and the great milestones accomplished to date.”

The Andrew McDonough B+ Foundation honors the life of Andrew McDonough, who battled leukemia at the age of 14. Since its inception in 2007, the B+ Foundation has funded over 150 critical, cutting-edge childhood cancer research grants and is the largest provider of financial assistance to families touched by this disease in the US.

“This second investment from the B+ Foundation is an important endorsement for Oncoheroes and continues to demonstrate that childhood cancer non-profits are willing to play a more active role in accelerating the development of new therapies,” said Ricardo Garcia, co-founder and CEO of Oncoheroes Biosciences. “Thanks, B+ Foundation, for continue backing this unique project.”

Thank You

Oncoheroes Biosciences And Fundación Olivares: It Is Time For New And Better Therapies

Pediatric oncologists are forced to adjust adult cancer treatments for childhood cancer due to insufficient specific therapies for children with cancer. To date, we only have six drugs developed and approved specifically for children with cancer, even though cancer is still the leading cause of death by disease in children.  Moreover, though being "cured" of cancer, childhood cancer survivors often experience late effects, both physical and psychological, secondary to their cancer or associated with the treatment's toxicity. For these reasons, Oncoheroes Biosciences was born to only focus on developing new and better therapies for pediatric oncology.

Oncoheroes is thrilled to announce the investment of Fundación Olivares, a childhood cancer non-profit from Málaga (Spain) founded in 2010 to help childhood cancer families. It is the first time Fundación Olivares goes beyond assisting families by supporting pediatric cancer research and investing in a biotech company.

“It took us more than 10 years to find a research project as closely aligned to our philosophy as Oncoheroes Biosciences," stated Andrés Olivares, founder of Fundación Olivares. “The confidence conveyed, Oncoheroes’ team professionalism, and the fact that they are developing specific medicines for children were key in our decision-making process to join this project.”

Fundación Olivares offers comprehensive help to families affected by childhood cancer and other serious chronic diseases through different activities such as psychological support, physiotherapy, speech therapy, balance and Reiki techniques, nutrition, school support, among others. 

“We are very pleased to end Childhood Cancer Awareness Month with the first childhood cancer organization outside the US joining this project,“ said Ricardo Garcia, Oncoheroes’ Co-Founder, and CEO. “We feel honored, and we want to thank Fundación Olivares for their trust and commitment to have an impact on pediatric drug development.”

Thank you

Oncoheroes Biosciences And The Scott Carter Foundation Are Onboard To End Childhood Cancer

Childhood cancer is considered a rare disease that accounts for about 1% of all U.S. cancer diagnoses. Because of improved tumor detection and treatment advances in recent decades, 84% of children with cancer now survive 5 years or more. However, cancer is still the first cause of death by disease among children in the U.S and 95.5% of the survivors will suffer from chronic health conditions by the age of 45. Oncoheroes Biosciences is working to reverse this situation by developing new pediatric oncology medicines.

We are excited to announce the investment of the Scott Carter Foundation (SCF), a childhood cancer non-profit located in Tulsa, Oklahoma founded in memory of Scott Carter, a 13-year old boy who died of osteosarcoma after a courageous three-year battle. During his fight against the disease, Scott built a remarkable collection of sports and celebrity memorabilia which he called “Scott Carter’s Heroes”. His dream was to display the collection for the enjoyment of the public and to raise money for children’s cancer research.

“It is appalling to note that a child diagnosed today would likely receive exactly the same treatment that was given to our son Scott as he battled bone cancer over thirty years ago. Today we have been given an opportunity of which we could only dream  - the opportunity to become partners with a biotech company that is 100% focused on pediatric cancers,” stated Paula Carter, co-founder and Executive Director of the Scott Carter Foundation. “It is with great pride and pleasure that the SCF has decided to join the efforts of Oncoheroes Biosciences so that we may move forward together, into the future with more hope than ever before of finding a cure for every child”.

The Scott Carter Foundation has focused its efforts on finding a cure for every child for over 28 years. In their attempt to “research the research”, they have found that thousands of research doctors across the US, Europe, and Canada give their lives to the search for a cure. Many, if not most of the greatest research projects remain underfunded. Thus, the Scott Carter Foundation has supported research fellowships at several institutions including M.D. Anderson, Texas Children’s Hospital, Children’s Hospital of Los Angeles, Duke University Medical Center among others. This is the first time the SCF is investing in a biotech company. 

“What an exciting Childhood Cancer Awareness Month! Scott Carter Foundation is the fourth foundation joining Oncoheroes within the last three weeks,” said Ricardo Garcia, co-founder, and CEO of Oncoheroes Biosciences. “Thank you, Scott Carter Foundation, for the confidence and for getting onboard with this unique endeavor”.

Thank you

Oncoheroes Biosciences And Arms Wide Open Childhood Cancer Foundation Fighting Childhood Cancer Together

Although cancer in children is considered rare, it is the leading cause of death by disease among children in the USA. Pediatric cancer differs significantly from adult cancers, both in physiology and mutations. However, the vast majority of drugs administered to children with cancer have been designed for adults. This could explain why current therapies fail in children and adolescents, being either ineffective or highly toxic.

Oncoheroes Biosciences is delighted to announce the investment of Arms Wide Open Childhood Cancer Foundation (AWOCCF), a non-profit headquartered in New Jersey. Since 2009, AWOCCF has funded over 80 research grants around the country, some of which have led to life-saving clinical trials, and has given over $1.2 million in family support, helping thousands of families.

“We are encouraged by the essential and critical work of Oncoheroes, and look forward to the future as we change the paradigm of childhood cancer TOGETHER!” said Dena Sherwood, Founder and President of AWOCCF. Dena Sherwood’s 13-month-old son Billy, Jr. was diagnosed with Stage IV high-risk neuroblastoma and is now a two-time cancer survivor.

Arms Wide Open Childhood Cancer Foundation is committed to funding pediatric cancer research, supporting families who are suffering hardship due to their child’s cancer diagnosis both financially and emotionally, educating the general public, raising awareness globally, and uniting the childhood cancer community. Moreover, under Dena’s leadership, Arms Wide Open is helping transform the childhood cancer landscape through their many initiatives, such as their Emmy-Award winning documentaries and awareness campaign, The Truth 365, which gives all children with cancer a voice, and by hosting, CureFest, an annual event in Washington, DC, that brings foundations and advocates together to speak as one voice on behalf of all children fighting cancer. 

“Thank you, Arms Wide Open Childhood Cancer Foundation, for your trust and willingness to adopt a new approach to bring safer and more effective treatments for children,” said Ricardo Garcia, co-founder, and CEO of Oncoheroes Biosciences. “We believe that building partnerships within childhood cancer stakeholders is a fantastic way to honor children and families affected by pediatric cancer this month and through the year.”

Thank you

Oncoheroes Biosciences And Swifty Foundation United Toward New Cures

Childhood cancer is considered a rare disease that accounts for about 1% of all U.S cancers. However, childhood cancer is not just one disease – there are more than 12 major types of pediatric cancers and over 100 subtypes. Although pediatric cancer death rates have declined over the past four decades due to improved tumor detection and treatment, for some types of cancer the survival rates remain devastating.

“The Swifty Foundation appreciates and is excited by Oncoheroes’ laser focus on pediatric oncology drug development. Swifty’s founder was treated with 30-year-old drugs and when his medulloblastoma returned his chance of survival dropped to 5% because there were no viable treatment options to offer,” stated Patti Gustafson, Executive Director of Swifty Foundation. “Oncoheroes drug discovery lab, dedicated to finding more effective and less toxic treatments using pediatric models, could be a game-changer for some cancer types like medulloblastoma”.

Michael Gustafson, the founder of the Swifty Foundation, chose to donate his tissue for research after his death at the age of 15 to help find a cure for pediatric brain cancer. Gift from a Child is a national initiative led by Swifty Foundation. The mission is to increase post mortem pediatric brain tissue donations and accelerate breakthrough cancer research, improve treatments and ultimately find new cures for childhood brain cancer. The Swifty Foundation is also focused on supporting research collaboration and medulloblastoma research. 

“We are excited to announce the investment of the Swifty Foundation during childhood cancer awareness month. September is time to advocate for and honor those who have been affected by childhood cancer, ”said Ricardo Garcia, co-founder, and CEO of Oncoheroes Biosciences. “Thank you, Swifty Foundation for joining our efforts to accelerate the discovery and development of new therapies for children and adolescents with cancer.”

Thank you

Oncoheroes Biosciences And Kier’s Kidz Helping Kids Beat Cancer Together

Every day, more than 800 children are diagnosed with cancer worldwide. After accidents, cancer is the second leading cause of death in children ages 1 to 14 in the US. Despite these facts, conventional drugs have rarely been developed specifically for pediatric cancer patients but are developed for adults and then tested in children.

However, cancer in children differs significantly from adult cancers, from the types of genetic changes that each age group exhibits to molecular characteristics, histology or outcome. The direct consequence of these differences is the failure of conventional therapies in children, both in terms of efficacy and toxicity.

Oncoheroes Biosciences is thrilled to announce the investment of Kier’s Kidz, a childhood cancer non-profit from New Jersey that for the first time invested in a biotech company. Since 2012, Kier’s Kidz has been helping children, adolescents, and young adults with cancer by funding cancer treatments and research.

Larry Perfetti, CEO and co-founder of Kier’s Kidz, said, “We are excited to be part of the Oncoheroes Family.  By investing in the work of Oncoheroes, we are investing in a 21st Century approach to pediatric cancer drug development that takes into account the advancements made in genetics, cancer research, pharmaceuticals, and medical knowledge about the specific needs of pediatric cancer patients. Most importantly, we are investing in the lives of pediatric cancer patients who will be helped to survive and to thrive by the new drugs that are developed by Oncoheroes specifically for these children and adolescents.”

Kier’s Kidz is Kiersten Hickman-Perfetti’s legacy of love and hope for children, adolescents and young adults with cancer. Kier lost her life at age twenty-two to alveolar rhabdomyosarcoma, a rare form of pediatric cancer. While fighting her own cancer for three-and-a-half years, Kier helped younger children and adolescents who were being treated for cancer in The Children's Hospital of Philadelphia.

“What a fantastic way to celebrate Childhood Cancer Awareness Month. Thank you, Kier’s Kidz for joining Oncoheroes. Coming together, we can finally change the landscape of pediatric oncology,” stated Ricardo Garcia, co-founder, and CEO of Oncoheroes Biosciences. “We can’t wait to share more exciting news this month, stay tuned”.

Thank You

Oncoheroes Biosciences And Children’s Cancer Research Fund Working Together For A World Without Childhood Cancer

Childhood cancer is still the first cause of death by disease among children in the U.S. Despite this, there are only five drugs specifically designed and approved for pediatric cancer to treat 12 types and multiple subtypes of childhood cancer. Due to insufficient specific therapies for children with cancer, pediatric oncologists are forced to adjust adult cancer treatments for them.

In 40 years Children’s Cancer Research Fund (CCRF) has contributed $213 million to research, education and awareness, and quality-of-life programs for childhood cancer families. Oncoheroes Biosciences is thrilled to announce an investment from CCRF.

“We are excited to support the vital work Oncoheroes is doing to accelerate new therapy options for children and adolescents with cancer,” stated Daniel Gumnit, CEO of the Children’s Cancer Research Fund. “It’s part of our organization’s commitment to making a real and meaningful impact for families who are battling cancer.”

Children’s Cancer Research Fund has worked closely with doctors and scientists to fund innovative research that has led to better treatments for kids battling cancer. CCRF’s mission is to remove the roadblocks that stand in the way of research breakthroughs, and they have a track record of success—from new drug trials for children with brain tumors and osteosarcoma to improvements in blood and marrow transplantation. CCRF’s success lies in their core values of innovation, impact and connection. CCRF develops strong relationships with the country’s top researchers and stay attuned to the ever-changing landscape of medical research.

“We are honored that a childhood cancer foundation with four decades of history has decided to join Oncoheroes. Thank you, Children’s Cancer Research Fund, for your trust. When we launched Oncoheroes, we wanted to involve the non-profit sector to help us bridge the valley of death in childhood cancer drug development. We are excited to see that this is happening and that together, we will accelerate the approval of new drugs for children and adolescents with cancer,”  explained Ricardo Garcia, co-founder, and CEO of Oncoheroes Biosciences.  

Thank You